Developer docs
API playgroundTry for free, no card

Search company profiles

Boston Heart Diagnostics

Full company profile

uuid0007mra

Namestring
Boston Heart Diagnostics
Legal namestring
Boston Heart Diagnostics Corporation
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Boston Heart Diagnostics Corporation is a specialty cardiovascular diagnostics laboratory headquartered in Framingham, Massachusetts. Founded in 2007 and operating as a wholly-owned subsidiary of Eurofins Scientific, the company runs a CAP-accredited and CLIA-certified clinical lab that delivers advanced cardiovascular disease (CVD) risk assessment to U.S. healthcare providers and their patients. Its core proposition targets the diagnostic gap that roughly 50% of patients who suffer a heart attack or stroke present with normal cholesterol on routine lipid panels; Boston Heart's menu is built to characterize hidden risk beyond standard lipids through proprietary methodologies including the HDL Map® (gel electrophoresis-based apoA-I quantification across five HDL subpopulations), Cholesterol Balance® (GC/MS measurement of sterol production and absorption markers), Fatty Acid Balance™ (saturated, trans, omega-3, and omega-6 profiling), and the Polygenic Risk Map™ (Illumina array-based PRS for CVD, diabetes, dementia, and cancer). The broader portfolio includes CVMap + Metabolics as a foundational panel, the CardioCognitive Genetic Profile, the GI Balance gut microbiome test, and over 50 Dried Blood Spot Tests that enable at-home sample collection with 96% correlation to venous draws.

The go-to-market is sales-led and provider-centric: physicians and cardiologists order tests through a secure provider portal, with results delivered back through the same channel and supported by Medical Science Liaisons, on-demand webinars, and continuing medical education. Patient-facing engagement runs through the mybostonheart.com portal, the 'In Good Health' blog, and the Boston Heart Lifestyle Program, which layers personalized nutrition plans and registered-dietitian coaching on top of test results (subscription pricing such as $33.75/month for the Diabetes Prevention Program). Revenue is generated primarily through professional-services billing of insurance carriers and health plans, supplemented by self-pay options and the Patient Assistance Support Services (PASS) program that provides discounts, payment plans, and financial assistance. The company is privately held, with its last disclosed financing being a 2010 Series A led by Bain Capital Ventures ($10M), and now operates under the Eurofins corporate umbrella without independent venture backing.

Operationally, Boston Heart emphasizes clinical credibility — the Founder and Chief Medical Officer Ernst J. Schaefer, MD, also serves as Laboratory Director and is the public face of the scientific content. The 2026 partnership with the NY Center for the Prevention of Heart Disease signals ongoing clinical-channel expansion, while scaling of the Dried Blood Spot menu and continued product launches (CVMap + Metabolics, Polygenic Risk Map) demonstrate sustained investment in the diagnostic surface despite the absence of recent equity capital.

Short descriptiontext

Boston Heart Diagnostics is a CAP-accredited, CLIA-certified specialty clinical laboratory that provides advanced cardiovascular disease risk assessment and personalized nutrition and lifestyle programs to U.S. healthcare providers and their patients, operating as a subsidiary of Eurofins Scientific.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersFramingham, United States
HQ citystring
Framingham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular diagnostic testing, advanced lipid panels, genetic cardiovascular testing, clinical laboratory services, dried blood spot testing
Industry4 codes
PRIMARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAH
Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Cardiovascular Diagnostic Testing Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Laboratory Testing Services
TypeProfessional Services
Description

Boston Heart Diagnostics generates revenue through laboratory diagnostic testing services billed to insurance carriers and health plans. The company directly bills insurance for services and also offers self-pay options including patient assistance programs.

bostonheartdiagnostics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details5 tiers
1One 20-Minute Coaching Session
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$19.99 per session

bostonheartdiagnostics.com
2One 50-Minute Coaching Session
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$39.99 per session

bostonheartdiagnostics.com
3Three 20-Minute Sessions Package
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$54.00 for three sessions

bostonheartdiagnostics.com
4Six 20-Minute Sessions Package
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$105.00 for six sessions

bostonheartdiagnostics.com
5Diabetes Prevention Program
ModelSubscriptionBilling cadenceMonthly
Notes

$33.75 per month

bostonheartdiagnostics.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1Boston Heart HDL Map
Description

Proprietary test quantifying HDL subpopulations using gel electrophoresis technique to assess CVD risk

bostonheartdiagnostics.com
+6 more records
Core offering1 text field

Boston Heart Diagnostics operates a CAP-accredited and CLIA-certified clinical laboratory that delivers advanced cardiovascular diagnostic testing, including advanced lipid panels, genetic testing, inflammation markers, metabolics, and Dried Blood Spot testing, to healthcare providers and their patients. The company supplements test results with personalized diagnostic reports, life plans, and the Boston Heart Lifestyle Program offering tailored nutrition plans and registered dietitian coaching.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 50% of patients who suffer a heart attack or stroke have normal cholesterol levels on routine tests
+1 more record
Product overview1 text field

Boston Heart Diagnostics offers a comprehensive diagnostic testing platform focused on cardiovascular disease prevention and management. The core portfolio centers on CVMap + Metabolics as the foundational test, complemented by exclusive proprietary tests including the Boston Heart HDL Map® Test, Boston Heart Cholesterol Balance® Test, and Boston Heart Fatty Acid Balance™ Test. The company provides extensive genetic testing through Polygenic Risk Map™ panels and the CardioCognitive Genetic Profile. Supporting the testing services are the Boston Heart Lifestyle Program offering personalized nutrition plans with registered dietitian coaching, and Dried Blood Spot Testing enabling over 50 tests from convenient fingertip samples. The platform also includes extensive patient and provider education resources including webinars, blog content, and medical education materials. All tests are analyzed in the company's CAP-accredited and CLIA-certified clinical laboratory.

Product and service10 records
1CVMap + Metabolics
CategoryCardiovascular Diagnostic Test
Description

Boston Heart's foundational comprehensive cardiovascular disease risk assessment test that augments standard lipid panels with advanced diagnostic biomarkers including lipids, Lp(a), inflammatory markers, metabolics, and Boston Heart's unique Cholesterol Balance reporting for actionable treatment strategies.

2Boston Heart HDL Map® Test
CategoryCardiovascular Diagnostic Test
Description

Proprietary test that quantifies apoA-I protein in five HDL subpopulations using gel electrophoresis, providing deeper CVD risk understanding by separating cardioprotective larger HDL particles from higher-risk smaller HDL particles.

3Boston Heart Cholesterol Balance® Test
CategoryCardiovascular Diagnostic Test
Description

Exclusive test measuring cholesterol production markers (lathosterol, desmosterol) and absorption markers (beta-sitosterol, campesterol, cholestanol) to guide statin and ezetimibe therapy selection for LDL-C lowering.

4Boston Heart Fatty Acid Balance™ Test
CategoryCardiovascular Diagnostic Test
Description

Test measuring major fatty acids including saturated, trans, omega-3, and omega-6 indices for cardiovascular disease characterization and management.

5Polygenic Risk Map™ - Male Complete
CategoryGenetic Cardiovascular Test
Description

Genetic test using Illumina Infinium Global Screening Array technology and Polygenic Risk Score analysis to assess genetic risk for multiple health conditions including coronary artery disease, stroke, diabetes, and various cancers.

6GI Balance Test
CategoryGut Microbiome Test
Description

Comprehensive gut microbiome assessment using genetic sequencing to evaluate metabolic pathways, bacterial balance, cardiovascular toxin producers, short-chain fatty acid production, and vitamin production.

7CardioCognitive Genetic Profile
CategoryGenetic Cardiovascular Test
Description

Genetic panel analyzing seven gene loci for cardiovascular disease risk, dementia risk, cognitive decline, aspirin benefit, statin-induced myopathy risk, and blood clot formation risk including APOE, KLOTHO, MTHFR, Factor V Leiden, and Factor 2 variants.

8Boston Heart Lifestyle Program
CategoryLifestyle Management Program
Description

Personalized lifestyle management program offering tailored nutrition plans, registered dietitian coaching, and life plans based on test results, health history, and food preferences to improve long-term patient health, including 20-minute and 50-minute coaching sessions and a Diabetes Prevention Program.

9Dried Blood Spot Testing
CategorySample Collection Method
Description

Convenient alternative to venous blood draws using fingertip blood samples dried onto an AdvanceDx 100 card, offering over 50 tests with 96% average correlation to liquid venous blood and accurate results at room temperature shipping.

10Apolipoprotein E (apoE) Genotype Test
CategoryGenetic Test
Description

Genetic test identifying APOE alleles (E2, E3, E4) to aid in selection of optimal cholesterol-lowering protocols and assess CVD and dementia risk.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1NY Center for the Prevention of Heart Disease
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-21
Description

The NY Center for the Prevention of Heart Disease has introduced advanced cholesterol testing services in partnership with Boston Heart Diagnostic Labs, offering detailed cardiovascular risk analysis including Apo B, LDL-Particle number, small Dense LDL, Lp(a), cardiometabolic markers, inflammatory cardiac markers, and genetic markers.

kitsapsun.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Quest Diagnostics is the largest US clinical reference laboratory and acquired Cleveland HeartLab, directly offering advanced cardiovascular and inflammation panels (e.g., NMR LipoProfile, CardioIQ). Comparable because it serves the same cardiologists and primary care providers with overlapping advanced lipid and inflammatory testing.

TypeBroad incumbent
Description

Labcorp is the second-largest US clinical reference lab with a broad cardiovascular menu including LDL-P, Lp(a), ApoB, and advanced inflammation markers. Comparable because it competes directly for the same advanced cardiovascular testing volume from US providers, although via a much larger generalist footprint.

TypeBroad incumbent
Description

Sonic Healthcare is a global medical diagnostics provider operating reference laboratories across the US, Europe, and Australia with cardiology and specialty testing services. Comparable because it provides specialty cardiovascular diagnostics within a large multinational reference-lab portfolio, similar to Eurofins/Boston Heart positioning.

TypeDirect peer
Description

ARUP is a nonprofit specialty reference laboratory operated by the University of Utah offering esoteric cardiovascular, lipid, and genetic testing. Comparable because it provides high-complexity specialty diagnostics for hospital systems and specialty practices using LDT-style methodology similar to Boston Heart.

TypeBroad incumbent
Description

Mayo Clinic Laboratories is the reference laboratory arm of Mayo Clinic offering esoteric cardiovascular, metabolic, and genetic testing globally. Comparable because it provides premium specialty diagnostics for advanced CV risk assessment leveraging academic clinical authority similar to Boston Heart's physician-led positioning.

TypeDirect peer
Description

Atherotech is a specialty cardiovascular diagnostics laboratory offering the VAP (Vertical Auto Profile) advanced lipid test and related CV risk markers. Directly comparable because it pioneered proprietary advanced lipid testing for cardiologists and preventive medicine physicians in the US market.

TypeDirect peer
Description

SpectraCell is a specialty clinical laboratory offering advanced cardiovascular, metabolic, micronutrient, and inflammation testing through a provider-based model. Comparable because it targets the same functional and preventive medicine channels with proprietary specialty panels.

TypeDirect peer
Description

Genova Diagnostics is a specialty clinical laboratory offering advanced cardiovascular, metabolic, gastrointestinal, and genetic testing. Comparable because it operates a similar provider-focused specialty lab model with proprietary panels and lifestyle/nutrition add-ons.

TypeEmerging player
Description

Metabolon provides metabolomics-based biomarker profiling services for clinical research, pharma, and advanced diagnostics including cardiovascular applications. Comparable because it operates in the metabolomics/biomarker testing space that intersects with Boston Heart's CVMap metabolics panel and TMAO testing.

TypeDirect peer
Description

PreventionGenetics is a CLIA-certified clinical DNA testing laboratory offering cardiovascular genetic testing panels and PGx. Comparable because it provides genetic cardiovascular and pharmacogenomic testing using similar clinical-lab LDT methodology as Boston Heart's Polygenic Risk Map and CardioCognitive Profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Boston Heart Diagnostics

Cardiovascular Diagnostic Testing Servicesbostonheartdiagnostics.com

Boston Heart Diagnostics is a CAP-accredited, CLIA-certified specialty clinical laboratory that provides advanced cardiovascular disease risk assessment and personalized nutrition and lifestyle programs to U.S. healthcare providers and their patients, operating as a subsidiary of Eurofins Scientific.

What Boston Heart Diagnostics does

Boston Heart Diagnostics Corporation is a specialty cardiovascular diagnostics laboratory headquartered in Framingham, Massachusetts. Founded in 2007 and operating as a wholly-owned subsidiary of Eurofins Scientific, the company runs a CAP-accredited and CLIA-certified clinical lab that delivers advanced cardiovascular disease (CVD) risk assessment to U.S. healthcare providers and their patients. Its core proposition targets the diagnostic gap that roughly 50% of patients who suffer a heart attack or stroke present with normal cholesterol on routine lipid panels; Boston Heart's menu is built to characterize hidden risk beyond standard lipids through proprietary methodologies including the HDL Map® (gel electrophoresis-based apoA-I quantification across five HDL subpopulations), Cholesterol Balance® (GC/MS measurement of sterol production and absorption markers), Fatty Acid Balance™ (saturated, trans, omega-3, and omega-6 profiling), and the Polygenic Risk Map™ (Illumina array-based PRS for CVD, diabetes, dementia, and cancer). The broader portfolio includes CVMap + Metabolics as a foundational panel, the CardioCognitive Genetic Profile, the GI Balance gut microbiome test, and over 50 Dried Blood Spot Tests that enable at-home sample collection with 96% correlation to venous draws.

The go-to-market is sales-led and provider-centric: physicians and cardiologists order tests through a secure provider portal, with results delivered back through the same channel and supported by Medical Science Liaisons, on-demand webinars, and continuing medical education. Patient-facing engagement runs through the mybostonheart.com portal, the 'In Good Health' blog, and the Boston Heart Lifestyle Program, which layers personalized nutrition plans and registered-dietitian coaching on top of test results (subscription pricing such as $33.75/month for the Diabetes Prevention Program). Revenue is generated primarily through professional-services billing of insurance carriers and health plans, supplemented by self-pay options and the Patient Assistance Support Services (PASS) program that provides discounts, payment plans, and financial assistance. The company is privately held, with its last disclosed financing being a 2010 Series A led by Bain Capital Ventures ($10M), and now operates under the Eurofins corporate umbrella without independent venture backing.

Operationally, Boston Heart emphasizes clinical credibility — the Founder and Chief Medical Officer Ernst J. Schaefer, MD, also serves as Laboratory Director and is the public face of the scientific content. The 2026 partnership with the NY Center for the Prevention of Heart Disease signals ongoing clinical-channel expansion, while scaling of the Dried Blood Spot menu and continued product launches (CVMap + Metabolics, Polygenic Risk Map) demonstrate sustained investment in the diagnostic surface despite the absence of recent equity capital.

Boston Heart Diagnostics firmographics

Firmographics
Name
Boston Heart Diagnostics
Legal name
Boston Heart Diagnostics Corporation
Website
https://bostonheartdiagnostics.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Boston Heart Diagnostics is a CAP-accredited, CLIA-certified specialty clinical laboratory that provides advanced cardiovascular disease risk assessment and personalized nutrition and lifestyle programs to U.S. healthcare providers and their patients, operating as a subsidiary of Eurofins Scientific.
Ownership category
akta.pro rank

Boston Heart Diagnostics industry classification

Industry
Product category
Cardiovascular Diagnostic Testing Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAALAH
Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing)

Keywords

  • Cardiovascular diagnostic testing
  • Advanced lipid panels
  • Genetic cardiovascular testing
  • Clinical laboratory services
  • Dried blood spot testing

Where Boston Heart Diagnostics is headquartered

Location

Headquarters

HQ city
Framingham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Boston Heart Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Laboratory Testing Services: Boston Heart Diagnostics generates revenue through laboratory diagnostic testing services billed to insurance carriers and health plans. The company directly bills insurance for services and also offers self-pay options including patient assistance programs.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goOne 20-Minute Coaching Session
Unit PricingPay-as-you-goOne 50-Minute Coaching Session
Unit PricingPay-as-you-goThree 20-Minute Sessions Package
Unit PricingPay-as-you-goSix 20-Minute Sessions Package
SubscriptionMonthlyDiabetes Prevention Program

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Boston Heart Diagnostics product offering

Product offering

Core offering

Boston Heart Diagnostics operates a CAP-accredited and CLIA-certified clinical laboratory that delivers advanced cardiovascular diagnostic testing, including advanced lipid panels, genetic testing, inflammation markers, metabolics, and Dried Blood Spot testing, to healthcare providers and their patients. The company supplements test results with personalized diagnostic reports, life plans, and the Boston Heart Lifestyle Program offering tailored nutrition plans and registered dietitian coaching.

Product overview

Boston Heart Diagnostics offers a comprehensive diagnostic testing platform focused on cardiovascular disease prevention and management. The core portfolio centers on CVMap + Metabolics as the foundational test, complemented by exclusive proprietary tests including the Boston Heart HDL Map® Test, Boston Heart Cholesterol Balance® Test, and Boston Heart Fatty Acid Balance™ Test. The company provides extensive genetic testing through Polygenic Risk Map™ panels and the CardioCognitive Genetic Profile. Supporting the testing services are the Boston Heart Lifestyle Program offering personalized nutrition plans with registered dietitian coaching, and Dried Blood Spot Testing enabling over 50 tests from convenient fingertip samples. The platform also includes extensive patient and provider education resources including webinars, blog content, and medical education materials. All tests are analyzed in the company's CAP-accredited and CLIA-certified clinical laboratory.

Differentiator

Problem solved

Functional benefit

Brands

  • Boston Heart HDL Map: Proprietary test quantifying HDL subpopulations using gel electrophoresis technique to assess CVD risk
  • Boston Heart Cholesterol Balance
  • Boston Heart Fatty Acid Balance
  • Polygenic Risk Map
  • CVMap
  • Boston Heart Lifestyle Program
  • Boston Heart Diagnostic Labs

Products and services

  • CVMap + Metabolics Boston Heart's foundational comprehensive cardiovascular disease risk assessment test that augments standard lipid panels with advanced diagnostic biomarkers including lipids, Lp(a), inflammatory markers, metabolics, and Boston Heart's unique Cholesterol Balance reporting for actionable treatment strategies.
  • Boston Heart HDL Map® Test Proprietary test that quantifies apoA-I protein in five HDL subpopulations using gel electrophoresis, providing deeper CVD risk understanding by separating cardioprotective larger HDL particles from higher-risk smaller HDL particles.
  • Boston Heart Cholesterol Balance® Test Exclusive test measuring cholesterol production markers (lathosterol, desmosterol) and absorption markers (beta-sitosterol, campesterol, cholestanol) to guide statin and ezetimibe therapy selection for LDL-C lowering.
  • Boston Heart Fatty Acid Balance™ Test Test measuring major fatty acids including saturated, trans, omega-3, and omega-6 indices for cardiovascular disease characterization and management.
  • Polygenic Risk Map™ - Male Complete Genetic test using Illumina Infinium Global Screening Array technology and Polygenic Risk Score analysis to assess genetic risk for multiple health conditions including coronary artery disease, stroke, diabetes, and various cancers.
  • GI Balance Test Comprehensive gut microbiome assessment using genetic sequencing to evaluate metabolic pathways, bacterial balance, cardiovascular toxin producers, short-chain fatty acid production, and vitamin production.
  • CardioCognitive Genetic Profile Genetic panel analyzing seven gene loci for cardiovascular disease risk, dementia risk, cognitive decline, aspirin benefit, statin-induced myopathy risk, and blood clot formation risk including APOE, KLOTHO, MTHFR, Factor V Leiden, and Factor 2 variants.
  • Boston Heart Lifestyle Program Personalized lifestyle management program offering tailored nutrition plans, registered dietitian coaching, and life plans based on test results, health history, and food preferences to improve long-term patient health, including 20-minute and 50-minute coaching sessions and a Diabetes Prevention Program.
  • Dried Blood Spot Testing Convenient alternative to venous blood draws using fingertip blood samples dried onto an AdvanceDx 100 card, offering over 50 tests with 96% average correlation to liquid venous blood and accurate results at room temperature shipping.
  • Apolipoprotein E (apoE) Genotype Test Genetic test identifying APOE alleles (E2, E3, E4) to aid in selection of optimal cholesterol-lowering protocols and assess CVD and dementia risk.

Quantifiable outcome

  • 50% of patients who suffer a heart attack or stroke have normal cholesterol levels on routine tests
  • +1 more outcomes

Companies that use Boston Heart Diagnostics

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Boston Heart Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Boston Heart Diagnostics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NY Center for the Prevention of Heart DiseaseminorStrategic or Co-development Partner · 21 May 2026The NY Center for the Prevention of Heart Disease has introduced advanced cholesterol testing services in partnership with Boston Heart Diagnostic Labs, offering detailed cardiovascular risk analysis including Apo B, LDL-Particle number, small Dense LDL, Lp(a), cardiometabolic markers, inflammatory cardiac markers, and genetic markers.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Boston Heart Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • Quest Diagnostics: Quest Diagnostics is the largest US clinical reference laboratory and acquired Cleveland HeartLab, directly offering advanced cardiovascular and inflammation panels (e.g., NMR LipoProfile, CardioIQ). Comparable because it serves the same cardiologists and primary care providers with overlapping advanced lipid and inflammatory testing.
  • Laboratory Corporation of America (Labcorp): Labcorp is the second-largest US clinical reference lab with a broad cardiovascular menu including LDL-P, Lp(a), ApoB, and advanced inflammation markers. Comparable because it competes directly for the same advanced cardiovascular testing volume from US providers, although via a much larger generalist footprint.
  • Sonic Healthcare: Sonic Healthcare is a global medical diagnostics provider operating reference laboratories across the US, Europe, and Australia with cardiology and specialty testing services. Comparable because it provides specialty cardiovascular diagnostics within a large multinational reference-lab portfolio, similar to Eurofins/Boston Heart positioning.
  • Mayo Clinic Laboratories: Mayo Clinic Laboratories is the reference laboratory arm of Mayo Clinic offering esoteric cardiovascular, metabolic, and genetic testing globally. Comparable because it provides premium specialty diagnostics for advanced CV risk assessment leveraging academic clinical authority similar to Boston Heart's physician-led positioning.

Direct peers

  • ARUP Laboratories: ARUP is a nonprofit specialty reference laboratory operated by the University of Utah offering esoteric cardiovascular, lipid, and genetic testing. Comparable because it provides high-complexity specialty diagnostics for hospital systems and specialty practices using LDT-style methodology similar to Boston Heart.
  • Atherotech Diagnostics Lab: Atherotech is a specialty cardiovascular diagnostics laboratory offering the VAP (Vertical Auto Profile) advanced lipid test and related CV risk markers. Directly comparable because it pioneered proprietary advanced lipid testing for cardiologists and preventive medicine physicians in the US market.
  • SpectraCell Laboratories: SpectraCell is a specialty clinical laboratory offering advanced cardiovascular, metabolic, micronutrient, and inflammation testing through a provider-based model. Comparable because it targets the same functional and preventive medicine channels with proprietary specialty panels.
  • Genova Diagnostics: Genova Diagnostics is a specialty clinical laboratory offering advanced cardiovascular, metabolic, gastrointestinal, and genetic testing. Comparable because it operates a similar provider-focused specialty lab model with proprietary panels and lifestyle/nutrition add-ons.
  • PreventionGenetics: PreventionGenetics is a CLIA-certified clinical DNA testing laboratory offering cardiovascular genetic testing panels and PGx. Comparable because it provides genetic cardiovascular and pharmacogenomic testing using similar clinical-lab LDT methodology as Boston Heart's Polygenic Risk Map and CardioCognitive Profile.

Emerging players

  • Metabolon: Metabolon provides metabolomics-based biomarker profiling services for clinical research, pharma, and advanced diagnostics including cardiovascular applications. Comparable because it operates in the metabolomics/biomarker testing space that intersects with Boston Heart's CVMap metabolics panel and TMAO testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Boston Heart Diagnostics social profiles

Digital presence

Boston Heart Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Boston Heart Diagnostics leadership team

Management profile

Number of profiles

Profiles6 records

Boston Heart Diagnostics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Boston Heart Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boston Heart Diagnostics

What does Boston Heart Diagnostics do?

Boston Heart Diagnostics operates a CAP-accredited and CLIA-certified clinical laboratory that delivers advanced cardiovascular diagnostic testing, including advanced lipid panels, genetic testing, inflammation markers, metabolics, and Dried Blood Spot testing, to healthcare providers and their patients. The company supplements test results with personalized diagnostic reports, life plans, and the Boston Heart Lifestyle Program offering tailored nutrition plans and registered dietitian coaching.

Is Boston Heart Diagnostics a public or private company?

Boston Heart Diagnostics is a private company. It is classified as corporate owned and is currently operating.

When was Boston Heart Diagnostics founded?

Boston Heart Diagnostics was founded in 2007. It employs 101 to 250 people.

Where is Boston Heart Diagnostics based?

Boston Heart Diagnostics is headquartered in Framingham, United States, in the North America region.

How does Boston Heart Diagnostics make money?

One revenue line is on record: laboratory Testing Services.

Who are Boston Heart Diagnostics's main competitors?

Broad incumbents on record are Quest Diagnostics, Laboratory Corporation of America (Labcorp), Sonic Healthcare and Mayo Clinic Laboratories. Direct peers are ARUP Laboratories, Atherotech Diagnostics Lab, SpectraCell Laboratories, Genova Diagnostics and PreventionGenetics. Metabolon is listed as an emerging player.

Does Boston Heart Diagnostics have an API?

No public API is recorded for Boston Heart Diagnostics.

What industry is Boston Heart Diagnostics in?

Boston Heart Diagnostics's product category is Cardiovascular Diagnostic Testing Services. Its primary akta.pro industry code is HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageNYC Coronary CT & Cholesterol Testing to Assess Heart Attack Risk AnnouncedThe NY Center for the Prevention of Heart Disease announced an expanded cardiovascular risk assessment program for asymptomatic people, combining Coronary CT Angiography with Cleerly and HeartFlow AI analysis and advanced cholesterol testing from Boston Heart Diagnostic Labs. The center cites Harvard Health and the Lancet, noting stress tests miss non-obstructive plaque ruptures and standard cholesterol tests miss over half of those at significant risk.Kitsap SunAdvanced Cholesterol Testing to Assess Heart Attack Risk: Lab Services AnnouncedThe NY Center for the Prevention of Heart Disease has introduced advanced cholesterol testing services in partnership with Boston Heart Diagnostic Labs, offering detailed cardiovascular risk analysis including Apo B, LDL-Particle number, small Dense LDL, Lpa, cardiometabolic markers, inflammatory cardiac markers, and genetic markers. The new testing addresses a critical gap: research from the American Heart Association shows a significant proportion of heart attack patients have cholesterol levels within the standard 'normal' range on routine tests, and over 60% of heart attack patients had no prior symptoms. Beyond cholesterol testing, the center integrates Coronary CT Angiography with Cleerly AI imaging and HeartFlow Analysis to identify coronary artery abnormalities that traditional stress testing frequently misses.EIN PresswireOnline Platform Lets Patients Order Specialty Lab Tests Without a Doctor’s VisitLab Test Shop, a direct-to-consumer lab testing marketplace, lets patients order specialty tests without a doctor's visit by using a network of 50-state-licensed providers to authorize orders. The platform connects users to over 20 independent specialty labs, excluding New York, New Jersey, and Rhode Island, and does not offer consultations or result interpretation.SustainvcBoston HeartBoston Heart Diagnostics is a company providing advanced diagnostics for cardiovascular disease and other chronic conditions. It was acquired by Eurofins Scientific in 2015.PR NewswireBoston Heart Diagnostics Launches LipoMap™: One of the Most Comprehensive Assessments of Lipid Metabolism AvailableBoston Heart Diagnostics announced the commercial launch of LipoMap™, a comprehensive lipid metabolism test panel comprising 33 lipid, lipoprotein, and apolipoprotein tests performed via high-resolution 600 MHz nuclear magnetic resonance spectroscopy. The test requires only 1 mL of blood, delivers results within a week, and is designed to identify hidden lipid abnormalities that contribute to cardiovascular disease even in patients on statin therapy or with normal LDL cholesterol levels. Boston Heart Diagnostics, a subsidiary of Eurofins Scientific, is positioning the tool as a means to enable greater personalization of treatment and targeted lifestyle interventions for patients at risk of cardiovascular disease.PR NewswireBoston Heart Diagnostics Launches LipidSeq™-- An NGS Test for Common Genetic Disorders of Lipid MetabolismBoston Heart Diagnostics, a subsidiary of Eurofins Scientific, announced the launch of LipidSeq™, a saliva-based next-generation sequencing test that identifies genetic causes of lipid and lipoprotein disorders associated with cardiovascular, pancreatic, kidney, and neurological diseases. The 23-gene test can detect conditions including familial hypercholesterolemia, lysosomal acid lipase deficiency, sitosterolemia, and other inherited lipid disorders, enabling early diagnosis and precision treatment. The test was developed in collaboration with Clinical Enterprise, which performs the genetic sequencing, and is available to healthcare providers through Boston Heart's customer care department.PR NewswireCoronavirus (COVID-19) Update: Daily RoundupThe U.S. Food and Drug Administration on July 17, 2020, issued warning letters to operators of two websites marketing unapproved COVID-19 products and approved a generic version of heparin sodium, an anti-coagulant used to prevent blood clotting. The agency also issued Emergency Use Authorizations to Boston Heart Diagnostics for its molecular COVID-19 RT-PCR test and to Luminex Corporation for its serology multi-antigen assay. To date, the FDA has authorized a total of 184 tests under EUAs during the pandemic response.Boston HeraldAntibody testing seen as key to breaking the coronavirus pandemicThe White House plans to ramp up coronavirus antibody testing with tens of millions of tests by May 1, as a Massachusetts lab launched its blood-based test. The testing could help return people to work and assign immune healthcare workers to high-risk patients. Experts say the data could guide reopening decisions.PrwebNewly Published Paper Introduces a Revolutionary Way to Assess, Track DietA paper in Medical Hypotheses introduces Diet Quality Photo Navigation, a pattern-recognition method to assess diet in under a minute. The method, developed by Diet ID, Inc., shows preliminary validation against the food frequency questionnaire. A study against blood biomarkers is ongoing in 100 adults.GlobeNewswire1st Choice Health & Wellness Now Offering Boston Heart Diagnostics1st Choice Health & Wellness in New Albany, Ind., now offers heart disease testing through Boston Heart Diagnostics. The program assesses risk via blood draw and questions, then provides follow-up for lifestyle changes. The clinic also offers chiropractic care and nutrition counseling.